Onego Bio’s precision-fermented egg replacer clears key FDA hurdle
The FDA’s “no questions” letter means the agency has reviewed Onego Bio’s safety dossier and found no reason to challenge its conclusion that the product is safe for consumption.
USA – Onego Bio, a Finnish food technology company that produces animal-free egg protein using precision fermentation, has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) issuing a “no questions” letter regarding its flagship product, Bioalbumen®.
This letter signifies that the FDA has no further questions or concerns about the company’s conclusion that Bioalbumen®, a precision-fermented egg protein, is Generally Recognized As Safe (GRAS) for use in various food and beverage applications.
Bioalbumen® is a bio-identical ovalbumin protein, produced via precision fermentation using the filamentous fungus Trichoderma reesei, a filamentous fungus, to produce ovalbumin; the primary protein found in egg whites, without the need for chickens.
It matches the amino acid sequence and functional properties of traditional chicken egg white protein.
The versatility of Bioalbumen® enables its use as a source of dietary protein and a functional ingredient for foaming, gelling, and binding in products ranging from baked goods and beverages (including eggnog and alcoholic egg white cocktails) to meat analogs, confections, sauces, ice cream, frozen yogurt, pudding, and more.
This precision fermentation method mimics nature’s protein synthesis, offering a sustainable and ethical alternative to conventional egg production.
The FDA’s “no questions” letter means the agency has reviewed Onego Bio’s safety dossier and found no reason to challenge its conclusion that the product is safe for consumption.
This clears the path for commercial launch in the U.S. food market, where demand for plant-based and animal-free ingredients continues to surge.
Additionally, the approval is timely, given the volatility in the egg market and supply chain disruptions exacerbated by recurring Avian Influenza outbreaks.
Unlike plant-based substitutes, which often struggle to replicate these properties, Onego’s product offers a molecularly identical protein, ensuring performance without compromise.
The company also announced plans to construct a flagship production facility in Jefferson County, Wisconsin, capable of producing an equivalent amount of egg protein to that produced by six million hens annually.
The FDA’s “no questions” letter not only validates Bioalbumen® as a reliable food solution but also positions Onego Bio as a leader in precision fermentation-based food ingredients in the evolving landscape of sustainable protein sources.
The company, a spin-off from VTT Technical Research Centre of Finland, has attracted attention for its science-driven approach and potential to disrupt the US$200 billion global egg market.
With the FDA hurdle cleared, Onego Bio plans to expand partnerships with food manufacturers and explore additional regulatory approvals in Europe and Asia.
The GRAS status also signals growing regulatory confidence in precision fermentation as a viable platform for producing animal-free proteins.
Overall, this regulatory green light strengthens Onego Bio’s position in the growing market for alternative proteins, supporting food manufacturers in their quest for resilient, innovative, and sustainable ingredient options amid supply chain uncertainty.
Sign up to HERE receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
